33 results
Actemra (tocilizumab)
(tocilizumab)Genentech, Inc.
Usage: ACTEMRA® (tocilizumab) is indicated for adults with moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, and for children aged 2 and older with polyarticular or systemic juvenile idiopathic arthritis. It also treats severe cytokine release syndrome and COVID-19 in hospitalized patients.
Activase (alteplase)
(Alteplase)Genentech, Inc.
Usage: Activase is indicated for the treatment of acute ischemic stroke, acute myocardial infarction (AMI) to reduce mortality and heart failure incidence, and lysis of acute massive pulmonary embolism with significant obstruction or unstable hemodynamics. Treatment should be initiated quickly, particularly for stroke within 3 hours of symptom onset.
Alecensa (alectinib hydrochloride)
(ALECTINIB HYDROCHLORIDE)Genentech, Inc.
Usage: ALECENSA is indicated for adjuvant treatment of resected ALK-positive non-small cell lung cancer (NSCLC) in adults and for the treatment of metastatic ALK-positive NSCLC in adults, both as detected by an FDA-approved test.
Avastin (bevacizumab)
(bevacizumab)Genentech, Inc.
Usage: Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer (in combination with chemotherapy), non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and advanced ovarian cancers (both sensitive and resistant). Additionally, it is used for unresectable hepatocellular carcinoma.
Cellcept (mycophenolate mofetil)
(Mycophenolate Mofetil)Genentech, Inc.
Usage: CELLCEPT (mycophenolate mofetil) is indicated for preventing organ rejection in adults and pediatric patients (3 months and older) receiving allogeneic kidney, heart, or liver transplants, used alongside other immunosuppressants.
Columvi (glofitamab)
(Glofitamab)Genentech, Inc.
Usage: COLUMVI is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma from follicular lymphoma, following two or more systemic therapies. Its approval is based on response rates, with continued approval pending clinical benefit confirmation.
Cotellic (cobimetinib)
(COBIMETINIB)Genentech, Inc.
Usage: COTELLIC® is indicated for treating adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with vemurafenib, and as a single agent for adult patients with histiocytic neoplasms.
Erivedge (vismodegib)
(vismodegib)Genentech, Inc.
Usage: ERIVEDGE is indicated for adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred post-surgery, or for those who are not suitable candidates for surgery or radiation.
Fuzeon (enfuvirtide)
(Enfuvirtide)Genentech, Inc.
Usage: FUZEON® is indicated for the treatment of HIV-1 infection in patients who are treatment-experienced and show evidence of ongoing HIV-1 replication despite current antiretroviral therapy, and it is used in combination with other antiretroviral agents.
Gavreto (pralsetinib)
(Pralsetinib)Genentech, Inc.
Usage: GAVRETO is indicated for treating adults with metastatic RET fusion-positive non-small cell lung cancer and for adults and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.